Business Context and Reporting Period
LeMaitre Vascular, Inc. (LMAT) filed a Form 8-K on June 22, 2020, reporting the consummation of a material asset acquisition and the entry into a new credit facility. The Company acquired the business and assets of Artegraft, Inc. related to its bovine carotid artery graft product.
Key Financial Metrics and Transaction Details
Acquisition Consideration
- Total Cash Consideration: $72,500,000 paid on the Closing Date.
- Escrow: $7,500,000 of the cash consideration was held in escrow until December 31, 2021.
- Funding Source: Cash on hand and a drawdown from a new credit facility.
- Contingent Consideration (Earn-Out):
- Year One (2021): $5,833,334 if 20,000 units sold.
- Year Two (2022): $5,833,333 if 24,000 units sold.
- Year Three (2023): $5,833,333 if 28,800 units sold.
- Catch-Up Payment: If aggregate sales over the three-year period reach 58,240 units, an additional payment may be made up to a maximum of $17,500,000.
Debt and Liquidity
- Term Loan Facility: $40,000,000 senior secured term loan maturing June 22, 2025.
- Revolving Credit Facility: $25,000,000 senior secured revolving credit facility maturing June 22, 2025.
- Interest Rates: Base rate + 1.50% or LIBOR + 2.50% initially; margins adjust downward after September 30, 2020.
- Amortization: Term loan amortizes quarterly starting September 30, 2020 (5% in Year 1, increasing to 10% in Years 4 and 5).
- Collateral: Obligations secured by a lien on substantially all Company assets.
Material Changes and Covenants
The filing represents a significant change in the Company's capital structure and asset base. The new Credit Agreement imposes strict financial covenants:
- Leverage Ratio: Consolidated leverage ratio limited to 3.00 to 1.00 (with potential increases following material acquisitions).
- Fixed Charge Coverage: Must maintain a ratio of no less than 1.25 to 1.00.
- Restrictive Covenants: Limits on incurring additional indebtedness, liens, mergers, changes of control, new business lines, and restricted payments.
Events of default include failure to make payments, insolvency, material misrepresentations, and change of control.
Outlook, Risks, and Contingencies
The Company's future cash outflows are contingent upon the sales performance of the acquired Artegraft product. Failure to meet the unit sales thresholds will result in lower total acquisition costs, while exceeding the aggregate threshold could trigger a significant additional payment of up to $17.5 million. The Company is now subject to the liquidity constraints and operational restrictions of the new Credit Agreement.
Investor Verification Checklist
- Verify the Company's current cash position to confirm the ability to service the new $40M term loan and $25M revolver.
- Monitor quarterly sales of the bovine carotid artery graft product to assess potential earn-out liabilities.
- Review subsequent filings for compliance with the 3.00:1.00 leverage ratio and 1.25:1.00 fixed charge coverage ratio.
- Assess the integration risks of the Artegraft assets and the impact on the Company's existing product portfolio.
- Confirm the status of the $7.5 million escrow release conditions as of December 31, 2021.